Skip to main content

Zimmer Biomet cash flow statement

  • ZBH · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$103.21−1.29%Close 13 Nov 2026

In fiscal 2025 (the year to 31 Dec 2025), Zimmer Biomet generated $1.70B of operating cash flow and $1.47B of free cash flow, after $224.5M of capital expenditure.

From Zimmer Biomet's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Zimmer Biomet cash flow statement, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Net income$773.2M$848.6M$717.4M$596.9M$760.8M$755.0M$780.4M$720.3M$147.0M$305.9M$1.81B−$379.2M$1.13B−$138.9M$401.6M$231.4M$1.02B$903.8M$705.1M$767.3M
Depreciation & amortization$230.0M$275.1M$337.4M$340.2M$359.9M$363.1M$358.5M$375.8M$712.4M$1.04B$1.06B$1.04B$1.01B$898.4M$937.7M$926.4M$951.7M$996.3M$1.09B$1.11B
Stock-based compensation$70.10M$69.90M$75.30M$62.00M$60.50M$55.00M$48.50M$49.40M$46.40M$57.30M$53.70M$65.50M$84.30M$73.80M$76.00M$105.0M$99.80M$101.0M$90.20M$97.10M
Operating cash flow$1.08B$1.04B$1.12B$1.19B$1.18B$1.15B$963.1M$1.06B$849.8M$1.63B$1.58B$1.75B$1.59B$1.08B$1.40B$1.28B$1.58B$1.50B$1.70B$1.88B
Operating cash flow margin27.8%25.2%27.3%28.3%26.4%25.8%20.8%22.7%14.2%21.2%20.3%22.0%19.9%17.6%20.6%18.5%21.4%19.5%20.6%22.0%
Capital expenditures$192.7M$250.0M$105.1M$79.20M$113.8M$114.7M$100.0M$144.9M$167.7M$184.7M$156.0M$162.7M$207.1M$111.9M$143.6M$187.9M$291.1M$203.8M$224.5M$241.1M
Acquisitions————$56.80M$59.00M$74.20M$54.30M$7.76B———————————
Free cash flow$891.7M$788.1M$1.01B$1.11B$1.06B$1.04B$863.1M$915.6M$682.1M$1.45B$1.43B$1.58B$1.38B$963.7M$1.26B$1.10B$1.29B$1.30B$1.47B$1.64B
Free cash flow margin22.9%19.1%24.7%26.4%23.9%23.2%18.7%19.6%11.4%18.8%18.3%20.0%17.3%15.7%18.5%15.8%17.5%16.9%17.9%19.2%
Free cash flow per share$3.75$3.45$4.69$5.54$5.63$5.89$5.02$5.33$3.59$7.15$7.00$7.79$6.67$4.66$5.99$5.22$6.15$6.35$7.41$8.45
Dividends paid—————$94.40M$132.4M$145.5M$157.1M$188.4M$193.6M$195.2M$196.7M$198.5M$200.1M$201.2M$200.9M$196.0M$190.3M$186.7M
Gross share repurchases$576.3M$737.0M$923.7M$505.6M$1.05B$485.6M$720.8M$400.9M$150.0M$415.5M—————$126.4M$692.2M$868.0M$487.0M$829.3M
Stock issuance proceeds$149.8M$57.00M$9.50M$16.90M$43.40M$46.90M$474.8M$284.7M$105.2M$136.6M$145.5M$107.9M$158.2M$129.8M$122.5M$78.10M$101.1M$82.10M$39.70M$27.50M
Net share repurchases$426.5M$680.0M$914.2M$488.7M$1.01B$438.7M$246.0M$116.2M$44.80M$278.9M−$145.5M−$107.9M−$158.2M−$129.8M−$122.5M$48.30M$591.1M$785.9M$447.3M$801.8M
Cash interest paid—$14.00M$17.00M$59.80M$55.00M$67.80M$68.10M$67.50M$207.1M$363.1M$317.5M$226.9M$193.1M$193.1M$219.0M$161.7M$200.6M$200.8M$298.4M—
Free cash flow after SBC$821.6M$718.2M$937.1M$1.05B$1.00B$982.2M$814.6M$866.2M$635.7M$1.39B$1.37B$1.52B$1.29B$889.9M$1.18B$991.8M$1.19B$1.19B$1.38B$1.55B

Quarterly

Zimmer Biomet cash flow statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Net income$419.2M$172.4M$242.8M$249.1M$239.5M$182.0M$152.8M$230.9M$139.3M$238.1M$198.3M$191.6M
Depreciation & amortization$241.2M$238.6M$243.2M$250.9M$263.6M$254.4M$271.8M$283.6M$284.0M$270.0M$270.8M$282.0M
Stock-based compensation$25.30M$29.00M$26.40M$24.50M$21.10M$19.60M$21.20M$25.30M$24.10M$24.20M$24.60M$24.20M
Operating cash flow$588.4M$228.0M$369.4M$395.7M$506.3M$382.8M$378.2M$418.7M$517.4M$359.4M$447.8M$560.0M
Operating cash flow margin30.3%12.1%19.0%21.7%25.0%20.1%18.2%20.9%23.1%17.2%20.6%27.1%
Capital expenditures$62.80M$55.10M$52.70M$44.50M$51.50M$44.60M$50.10M$55.00M$74.80M$36.30M$54.20M$75.80M
Free cash flow$525.6M$172.9M$316.7M$351.2M$454.8M$338.2M$328.1M$363.7M$442.6M$323.1M$393.6M$484.2M
Free cash flow margin27.1%9.2%16.3%19.3%22.5%17.7%15.8%18.2%19.7%15.5%18.1%23.5%
Free cash flow per share$2.52$0.84$1.53$1.73$2.27$1.69$1.65$1.83$2.24$1.65$2.04$2.53
Dividends paid$50.20M$49.40M$49.40M$49.20M$48.00M$47.80M$47.50M$47.50M$47.50M$46.90M$46.50M$45.80M
Gross share repurchases$410.3M$113.6M$85.90M$596.3M$72.20M$229.8M$7.20M$0.00$250.0M$250.1M$250.7M$78.50M
Stock issuance proceeds$19.30M$56.40M$6.60M$18.60M$500.0K$16.70M$400.0K$20.90M$1.70M$12.30M$100.0K$13.40M
Net share repurchases$391.0M$57.20M$79.30M$577.7M$71.70M$213.1M$6.80M−$20.90M$248.3M$237.8M$250.6M$65.10M
Free cash flow after SBC$500.3M$143.9M$290.3M$326.7M$433.7M$318.6M$306.9M$338.4M$418.5M$298.9M$369.0M$460.0M

The main figures as JSON and plain text. See data and methodology.

ZBH in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.